Welcome to our dedicated page for Medicure news (Ticker: MCUJF), a resource for investors and traders seeking the latest updates and insights on Medicure stock.
Medicure Inc. (MCUJF) generates regular news flow through financial results, pharmacy acquisitions and updates on its U.S. pharmaceutical and healthcare product operations. The company describes itself as focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, with a present focus on AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets.
News items commonly include quarterly and year-end financial results, where Medicure reports revenue from AGGRASTAT, ZYPITAMAG, and its pharmacy businesses. These releases often discuss performance of Marley Drug, Gateway Medical Pharmacy and West Olympia Pharmacy, as well as research and development spending, including work on the investigational product MC-1 for PNPO deficiency.
Investors following MCUJF can also find announcements about corporate transactions, such as the acquisitions of Gateway Medical Pharmacy and West Olympia Pharmacy through Medicure’s U.S. subsidiary. The company’s news regularly provides details on how these acquisitions relate to its direct-to-consumer pharmacy expansion and support for marketed products like ZYPITAMAG and BRENZAVVY.
Medicure also issues notices about upcoming investor conference calls and webcasts for its quarterly and annual results, including dial-in details and access codes. This news page aggregates those releases so readers can review historical announcements and monitor ongoing developments in Medicure’s pharmaceutical and pharmacy operations.
Medicure reported a net revenue of $11.6 million for the year ended December 31, 2020, down from $20.2 million in 2019. Quarterly revenue also decreased to $2.4 million from $3.5 million. AGGRASTAT® sales dropped to $10.6 million due to reduced volumes from COVID-19 impacts. Conversely, ZYPITAMAG® and Marley Drug contributed $453,000 and $340,000 respectively. The adjusted EBITDA was negative $3.9 million, in line with 2019. The net loss for 2020 was $6.8 million, a significant reduction from $19.8 million in 2019. Unrestricted cash fell to $2.7 million from $13.0 million.
Medicure Inc. will participate in Renmark Financial Communications' live Virtual Non-Deal Roadshow on March 30, 2021, at 1:00 PM EST. This event aims to present the latest investor insights and will feature Dr. Albert Friesen, CEO and Chairman. Stakeholders and investors are invited to register for the live session, which will also include a Q&A segment. Limited registration is available, but a replay will be accessible on Medicure's website afterward. Medicure focuses on cardiovascular therapies in the U.S.
Medicure Inc. (OTC: MCUJF) announced participation in Renmark Financial Communications' Virtual Non-Deal Roadshow on March 9, 2021, at 12:00 PM EST. The event aims to present the latest investor insights featuring CEO Dr. Albert Friesen, followed by a live Q&A. Stakeholders and investors are invited to register for the event, with access to a replay available on the company’s website. Medicure focuses on therapies in the U.S. cardiovascular market, including AGGRASTAT® and ZYPITAMAG®.
Medicure Inc. (TSXV: MPH, OTC: MCUJF) announced its participation in Renmark Financial Communications' Virtual Non-Deal Roadshow on February 23, 2021, at 12:00 PM EST. CEO Albert Friesen will present the latest investor insights and engage in a Q&A session. Stakeholders are encouraged to register for this live event, which may have limited capacity, although a replay will be available on the company’s website. Medicure specializes in cardiovascular therapies, including AGGRASTAT® and ZYPITAMAG® in the U.S., and runs Marley Drug, a pharmacy providing a mail-order drug program.
Medicure Inc. (OTC:MCUJF) will participate in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series on February 8, 2021, at 2:00 PM EST. CEO Albert Friesen will present the latest investor information, followed by a live Q&A session. Stakeholders and investors can register for this event through the provided link. Limited registration may apply, but a replay will be available on Medicure's website. The company focuses on cardiovascular therapies in the U.S. market, including AGGRASTAT and ZYPITAMAG.
Medicure has entered into a License, Manufacture and Supply Agreement with Reliance Life Sciences for a cardiovascular biosimilar. This deal grants Medicure exclusive rights to market the product in the U.S., Canada, and the European Union. Medicure will oversee the regulatory approval process. CEO Dr. Albert Friesen expressed optimism about growing their cardiovascular portfolio. The partnership aims to enhance Medicure's market positioning and revenue potential in the cardiovascular segment.
Medicure Inc. (OTC: MCUJF) has reported promising early clinical findings for AGGRASTAT® (tirofiban hydrochloride) in the treatment of thrombotic complications associated with COVID-19. A small proof of concept study showed significant improvements in oxygen levels in patients treated with AGGRASTAT® alongside standard care. The company plans to evaluate further randomized clinical studies in the U.S. to confirm efficacy and safety for COVID-19 patients. Importantly, AGGRASTAT® is not currently approved for COVID-19 treatment nor claims to eliminate the virus.
Medicure has terminated its marketing agreement with Sensible Medical Innovations for the ReDS Pro™ device in the U.S. The decision aligns with a strategic review and allows Medicure to concentrate on its own higher-margin products, AGGRASTAT® and ZYPITAMAG™. The termination includes a transition agreement that provides additional compensation for customer leads to Medicure. Medicure retains a 7.71% equity interest in Sensible, indicating ongoing support for the company during its transition.